Drug intelligence / Profile preview

CTN-005

Development stage
Preclinical
Lead developer
Centenaire Biosciences
Modality
Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Parenteral
01

Overview

CTN-005 is an Fc-engineered monoclonal antibody developed by Centenaire Biosciences. It is designed to target both the epidermal growth factor receptor (EGFR) and c-Met (hepatocyte growth factor receptor), functioning as a dual antagonist and inhibitor of these pathways. The drug’s mechanism includes EGFR antagonism and c-Met inhibition, with additional immunotherapeutic effects such as antibody-dependent cell cytotoxicity and immunostimulation. Its primary indication is for the treatment of non-small cell lung cancer (NSCLC), with potential applications in other neoplasms and respiratory diseases. As of the latest updates, CTN-005 remains in preclinical development[1][2].

02

Targets

EGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on CTN-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTN-005.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call